Advertisement

Topics

Galapagos NV: GLPG1690 halts disease progression in IPF patients in FLORA Phase 2a trial

16:04 EDT 9 Aug 2017 | FinanzNachrichten

Forced vital capacity (FVC) in lungs stabilized over the 12-week treatment period, placebo arm showed expected decline Functional respiratory imaging (FRI) confirms FVC data with statistical signi...

Original Article: Galapagos NV: GLPG1690 halts disease progression in IPF patients in FLORA Phase 2a trial

NEXT ARTICLE

More From BioPortfolio on "Galapagos NV: GLPG1690 halts disease progression in IPF patients in FLORA Phase 2a trial"

Quick Search
Advertisement
 

Relevant Topic

Respiratory
Asthma COPD Cystic Fibrosis Pneumonia Pulmonary Medicine Respiratory Respiratory tract infections (RTIs) are any infection of the sinuses, throat, airways or lungs.  They're usually caused by viruses, but they can also ...